TY - JOUR
T1 - Recommendations for management of patients with neuroendocrine liver metastases
AU - Frilling, Andrea
AU - Modlin, Irvin M.
AU - Kidd, Mark
AU - Russell, Christopher
AU - Breitenstein, Stefan
AU - Salem, Riad
AU - Kwekkeboom, Dik
AU - Lau, Wan yee
AU - Klersy, Catherine
AU - Vilgrain, Valerie
AU - Davidson, Brian
AU - Siegler, Mark
AU - Caplin, Martyn
AU - Solcia, Enrico
AU - Schilsky, Richard
N1 - Funding Information:
This consensus conference was endorsed and sponsored by the European-African Hepato-Pancreatico-Biliary Association (E-AHPBA), Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS), European Neuroendocrine Tumour Society (ENETS), European Society of Surgical Oncology (ESSO), Great Britain and Ireland Hepato Pancreatico Biliary Association (GBIHPBA), International Hepato Pancreatico Biliary Association (IHPBA), International Liver Transplantation Society (ILTIS), United Kingdom and Ireland Neuroendocrine Tumour Society (UKINET), NET Patient Foundation, and Carcinoid Foundation. We acknowledge the generous financial support from companies including Ipsen, SIRTeX, Novartis, Applied Accelerator Applications, Pfizer, Covidien, and Sanofi. These companies were involved neither in the selection of topics nor in the choice of experts or jury members. Only the jury and authors were involved in the development of the manuscript and the recommendations. The conference was also supported by a grant from the Dr Heinz-Horst Deichmann Foundation and Imperial College London. We thank Dr Martina Gosteli and her team at the University of Zurich for their help with reviewing the literature. Additional meeting information, text, and references are included in the appendix .
PY - 2014/1
Y1 - 2014/1
N2 - Many management strategies exist for neuroendocrine liver metastases. These strategies range from surgery to ablation with various interventional radiology procedures, and include both regional and systemic therapy with diverse biological, cytotoxic, or targeted agents. A paucity of biological, molecular, and genomic information and an absence of data from rigorous trials limit the validity of many publications detailing management. This Review represents the views from an international conference, for which 15 expert working groups prepared evidence-based assessments addressing specific questions, and from which an independent jury derived final recommendations. The aim of the conference was to review the existing approaches to neuroendocrine liver metastases, assess the evidence on which management decisions were based, develop internationally acceptable recommendations for clinical practice (when evidence was available), and make recommendations for clinical and research endeavours. This report represents the final clinical statements and proposals for future research.
AB - Many management strategies exist for neuroendocrine liver metastases. These strategies range from surgery to ablation with various interventional radiology procedures, and include both regional and systemic therapy with diverse biological, cytotoxic, or targeted agents. A paucity of biological, molecular, and genomic information and an absence of data from rigorous trials limit the validity of many publications detailing management. This Review represents the views from an international conference, for which 15 expert working groups prepared evidence-based assessments addressing specific questions, and from which an independent jury derived final recommendations. The aim of the conference was to review the existing approaches to neuroendocrine liver metastases, assess the evidence on which management decisions were based, develop internationally acceptable recommendations for clinical practice (when evidence was available), and make recommendations for clinical and research endeavours. This report represents the final clinical statements and proposals for future research.
UR - http://www.scopus.com/inward/record.url?scp=84891369262&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891369262&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(13)70362-0
DO - 10.1016/S1470-2045(13)70362-0
M3 - Review article
AN - SCOPUS:84891369262
VL - 15
SP - e8-e21
JO - The Lancet Oncology
JF - The Lancet Oncology
SN - 1470-2045
IS - 1
ER -